JPMorgan Chase & Co. boosted its stake in Evolent Health Inc. (NYSE:EVH) by 3.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,338,238 shares of the company’s stock after buying an additional 47,773 shares during the period. JPMorgan Chase & Co. owned 3.14% of Evolent Health worth $25,694,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. California State Teachers Retirement System raised its position in shares of Evolent Health by 14.0% in the second quarter. California State Teachers Retirement System now owns 31,915 shares of the company’s stock valued at $613,000 after buying an additional 3,912 shares during the last quarter. Swiss National Bank raised its position in shares of Evolent Health by 90.2% in the second quarter. Swiss National Bank now owns 32,900 shares of the company’s stock valued at $632,000 after buying an additional 15,600 shares during the last quarter. Dowling & Yahnke LLC raised its position in shares of Evolent Health by 100.0% in the second quarter. Dowling & Yahnke LLC now owns 40,000 shares of the company’s stock valued at $768,000 after buying an additional 20,000 shares during the last quarter. Emerald Acquisition Ltd. purchased a new position in shares of Evolent Health during the second quarter valued at about $1,301,000. Finally, Geode Capital Management LLC raised its position in shares of Evolent Health by 1.3% in the first quarter. Geode Capital Management LLC now owns 75,085 shares of the company’s stock valued at $792,000 after buying an additional 948 shares during the last quarter. 41.96% of the stock is currently owned by institutional investors.

Shares of Evolent Health Inc. (NYSE:EVH) traded down 1.14% during midday trading on Friday, reaching $22.54. The company’s stock had a trading volume of 413,896 shares. The company’s market capitalization is $1.36 billion. Evolent Health Inc. has a 1-year low of $8.14 and a 1-year high of $26.84. The stock has a 50 day moving average of $24.25 and a 200-day moving average of $17.31.

Evolent Health (NYSE:EVH) last issued its quarterly earnings data on Thursday, August 4th. The company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.04. The firm had revenue of $56.50 million for the quarter, compared to analyst estimates of $51.96 million. Evolent Health had a negative net margin of 76.55% and a negative return on equity of 5.04%. The firm’s revenue was up 443.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.95) EPS. On average, equities research analysts anticipate that Evolent Health Inc. will post ($0.54) earnings per share for the current year.

A number of equities analysts recently issued reports on the company. Canaccord Genuity assumed coverage on Evolent Health in a report on Wednesday, June 1st. They set a “buy” rating on the stock. FBR & Co raised their price target on Evolent Health from $16.00 to $24.00 and gave the stock an “outperform” rating in a report on Wednesday, July 13th. Leerink Swann reissued an “outperform” rating and set a $20.00 price target on shares of Evolent Health in a report on Sunday, July 17th. Finally, Jefferies Group assumed coverage on Evolent Health in a report on Tuesday, July 26th. They set a “buy” rating and a $28.00 price target on the stock. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Evolent Health currently has a consensus rating of “Buy” and an average target price of $22.50.

In other news, major shareholder Board Co Advisory sold 1,936,529 shares of the company’s stock in a transaction dated Wednesday, September 14th. The shares were sold at an average price of $22.50, for a total value of $43,571,902.50. Following the sale, the insider now owns 4,445,879 shares in the company, valued at approximately $100,032,277.50. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Thomas Peterson III sold 72,827 shares of the company’s stock in a transaction dated Wednesday, September 14th. The shares were sold at an average price of $21.54, for a total transaction of $1,568,693.58. Following the completion of the sale, the chief operating officer now owns 377,623 shares in the company, valued at approximately $8,133,999.42. The disclosure for this sale can be found here. 8.85% of the stock is currently owned by insiders.

About Evolent Health

Evolent Health, Inc supports integrated health systems in their migration towards value-based care and population health management. The Company’s services include providing customers with a population management platform, integrated data and analytics capabilities, pharmacy benefit management services and health plan administration services.

5 Day Chart for NYSE:EVH

Receive News & Ratings for Evolent Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.